ReportGem ReportGem 中文

REAL-TIME GLOBAL RESEARCH

Powering even further ahead

Published: 2026-08-03Institution: BofA Global ResearchPages: 9Original language: English

Research evidence excerpt

Accessible version

IMI

Powering even further ahead

Reiterate Rating: BUY | PO: 3,400 GBp | Price: 2,936 GBp

Power, Nuclear and LNG drive order growth

03 August 2026

1H26 results beat expectations by 2% on revenues, with organic growth 90bps ahead

and operating leverage driving operating profits 4% above consensus. Despite the

strong 1H, we expect FY26 numbers in line with guidance (MSD organic growth and

slight YoY margin expansion, implying a >20% margin), modelling 5.1% organic growth

(cons 5%) and margins of 20.3% (cons 20.2%), with 2H facing a tougher growth comp

and some profitability drag from cyber-security investments. More importantly, 2Q

confirmed a strong medium-term growth outlook for Process Automation, with OE

Power orders up 100% organically (largely to gas turbine OEMs), a major nuclear OE

order, robust nuclear AM (orders +33% YoY) and LNG OE orders up 67% YoY. This

reinforces our thesis that consensus underestimates IMI's automation growth (read:

Powering ahead). Our 2027/28 automation organic growth estimates of 6.2%/6.5% sit

120/180bps ahead of consensus. We raise group adj. EBITA by c.2% in FY26-28 on

strong delivery and an improving growth outlook, leaving us 4-5% ahead of consensus in

FY27/28. PO moves from 3,300p to 3,400p and we reiterate Buy.

Equity

DC exposure increasingly supports Life Tech growth

Benjamin Heelan >>

Research Analyst

Merrill Lynch (DIFC)

Within Life Technology, IMI supplies precision fluid-control content and miniature valves,

into DC liquid cooling systems. While management had guided to c.GBP30m of orders in

FY26, 1H already delivered GBP18m (+200% YoY); we therefore expect IMI to book

c.GBP40m of orders in 2026, which typically convert to revenue within weeks, equivalent

to c.5% of Life Technology revenues. Strong end-market growth alongside share gains

underpins our subsegment growth expectation of 30%/25%, supporting Life Technology

organic growth estimates of 6%/5% in FY27/28, 140/100bps ahead of consensus.

Rerating potential and more buybacks through 2028E

At c.14x EV/EBITA FY2, IMI trades at a slight premium to its history, but shows improved

profitability and cash generation.…

The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.

Open report viewer